Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Keyphrases

• Recent Advances 100%
• Pseudomonas Aeruginosa (P. aeruginosa) 100%
• Cystic Fibrosis 100%
• Pseudomonas Aeruginosa Infection 100%
• Suppressive Therapy 66%
• Biofilm 66%
• Lung Infection 66%
• Lung Function 66%
• Inhalation Therapy 66%
• P. Aeruginosa Infection 66%
• Clinical Trials 33%
• Antibiotics 33%
• Mucoid Strain 33%
• Sputum 33%
• Patient-reported Outcomes 33%
• Antibiotic Prophylaxis 33%
• Antibiotic Therapy 33%
• Lung Inflammation 33%
• Ciprofloxacin 33%
• Small Clinical Trials 33%
• Acute Exacerbation 33%
• Quinolones 33%
• Anti-Pseudomonas 33%
• Long-term Prophylaxis 33%
• Inhalation Treatment 33%
• Old Antibiotics 33%
• Inhaled Tobramycin 33%
• Function Time 33%
• Aztreonam Lysine 33%
• Azithromycin 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Pseudomonas aeruginosa 100%
• Cystic Fibrosis 100%
• Pseudomonas Infection 100%
• Infection 40%
• Lung Infection 40%
• Antibiotic Agent 40%
• Clinical Trial 20%
• Quinolone Derivative 20%
• Antibiotic Therapy 20%
• Antibiotic Prophylaxis 20%
• Pneumonia 20%
• Ciprofloxacin 20%
• Tobramycin 20%
• Pseudomonas 20%
• Azithromycin 20%
• Aztreonam Lysine 20%